X4 Pharmaceuticals, Inc
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
XFOR$3.33+4.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets F-
X4 PHARMACEUTICALS INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
| December 31,2024 | December 31,2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $55,699 | $99,216 |
| Accounts receivable | 1,070 | — |
| Marketable securities | 46,361 | 15,000 |
| Research and development incentive receivable | 640 | 562 |
| Inventory | 2,817 | — |
| Prepaid expenses and other current assets | 5,588 | 7,298 |
| Total current assets | 112,175 | 122,076 |
| Property and equipment, net | 776 | 745 |
| Goodwill | 17,351 | 17,351 |
| Intangible asset, net | 10,000 | — |
| Right-of-use assets | 4,065 | 5,650 |
| Other assets | 2,080 | 1,436 |
| Total assets | $146,447 | $147,258 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $8,621 | $8,947 |
| Accrued expenses | 23,005 | 12,816 |
| Current portion of lease liability | 1,251 | 1,099 |
| Total current liabilities | 32,877 | 22,862 |
| Long-term debt, including accretion, net of discount | 75,425 | 54,570 |
| Lease liabilities | 1,410 | 2,612 |
| Warrant liability (Note 5) | 13,755 | 15,683 |
| Other liabilities | 831 | 432 |
| Total liabilities | 124,298 | 96,159 |
| Commitments and contingencies (Note 12) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value. 10,000,000 shares authorized and no shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | — | — |
| Common stock, $0.001 par value. 500,000,000 shares authorized as of December 31, 2024 and December 31, 2023, respectively; 170,946,943 and 167,434,595 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | 171 | 167 |
| Additional paid-in capital | 537,455 | 528,956 |
| Accumulated other comprehensive loss | (122) | (119) |
| Accumulated deficit | (515,355) | (477,905) |
| Total stockholders’ equity | 22,149 | 51,099 |
| Total liabilities and stockholders’ equity | $146,447 | $147,258 |
| The accompanying notes are an integral part of these consolidated financial statements | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.